Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Stromedix raises $25mm in Series B for fibrosis programs

Executive Summary

Stromedix (fibrotic disease therapeutics) has completed a $25mm Series B round led by New Leaf Venture Partners along with other new investors Bessemer Venture Partners and Red Abbey Venture Partners. Returning backers Atlas Venture and Frazier Healthcare Ventures also participated in the financing. New Leaf's Ron Hunt and Bessemer's Chris Gabrieli will join Stromedix's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies